

Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection

SUPPLEMENTARY APPENDIX

Table of Contents

Covid-19 Phase 3 Prevention Trial Team (REGN 2069/CoVPN 3502)	3
Study Sites and Investigators	3
Regeneron Study Team.....	12
NIAID/CoVPN Team	14
Supplementary Methods	15
Trial Oversight	15
Stratification.....	16
Inclusion and Exclusion Criteria.....	17
Covid-19 Signs and Symptoms – Broad-Term, Strict-Term, and CDC Definitions	21
Pharmacokinetic Analysis Methods	24
Additional Statistical Methods.....	26
Supplementary Figures	28
Figure S1. Schematic Overview of the Study Design	28
Figure S2. Flow Diagram for the Analysis Population.....	29
Figure S3. Mean Viral Load in Symptomatic and Asymptomatic SARS-CoV-2 PCR+ Individuals.....	30
Figure S4. Viral Load Over Time in the Placebo Arm by Baseline Serology Status ..	31
Figure S5. Mean (+SD) Concentrations of REGN10933 and REGN10987 in Serum Over Time (Part B Sentinel Group).....	32
Figure S6. Mean (+SD) Concentrations of REGN10933 and REGN10987 in Serum Over Time (Part B Sentinel + Safety Group)	33
Supplementary Tables	34
Table S1. Demographics and Baseline Characteristics (Seropositive).....	34
Table S2. Proportion of Participants Who Had a Symptomatic RT-qPCR-Confirmed SARS-CoV-2 Infection (Broad-Term) by Period (Seronegative).....	36
Table S3. Proportion of Participants Who Had a Symptomatic RT-qPCR-confirmed SARS-CoV-2 Infection by Definition (Seronegative).....	37
Table S4: Summary of Viral Load Endpoints (Seronegative)*	38
Table S5. Proportion of Participants Who Had a Covid-19-related Hospitalization or ER Visit (Seronegative)	40
Table S6. Proportion of Participants Who Had a Symptomatic RT-qPCR-Confirmed SARS-CoV-2 Infection (Broad-Term) by Baseline Serology Status.....	41

Table S7. Number of Weeks of Symptomatic SARS-CoV-2 Infection (Broad-Term) by Baseline Serology Status.....	42
Table S8. Number of Weeks of High Viral Load (>4 log ₁₀ copies/mL) in Nasopharyngeal Swab Samples by Baseline Serology Status	43
Table S9. Maximum SARS-CoV-2 RT-qPCR Viral Load (log ₁₀ copies/mL) in Nasopharyngeal Swab Samples by Baseline Serology Status	44
Table S10. Number of Weeks of RT-qPCR Confirmed SARS-CoV-2 Infection (Regardless of Symptoms) by Baseline Serology Status	45
Table S11. Treatment-Emergent Adverse Events Occurring in ≥2% of Participants .	46
Table S12. Serious Treatment-Emergent Adverse Events	47
Table S13. Summary of PK Parameters for Casirivimab and Imdevimab After a Single 1200 mg Subcutaneous Dose of REGEN-COV in Part B Participants	48

Covid-19 Phase 3 Prevention Trial Team (REGN 2069/CoVPN 3502)

Study Sites and Investigators

Advanced Pulmonary Research Institute, Loxahatchee, FL: Neal Warshoff, Liudmila Moreiras

AGA Clinical Trials, Miami, FL: Dario Altamirano, Dickson Ellington, Faisal Faikih

AMR-Knoxville (formerly NOCCR), Knoxville, TN: William Smith, Richard Gibson, Katie Buckner

Ardmore Medical Research, Winston Salem, NC: Robert Rosen, Amy Sapp

Arizona Liver Health, Tucson, AZ: Anita Kohli, Vicki McIntyre, Yessica Sachdeva

Arizona Liver Health, Chandler, AZ: Yessica Sachdeva, Anita Kohli, Amanda McFarland, Dina Gibson

Ark Clinical Research, Long Beach, CA: Kenneth Kim, Jason Ahn, Lisa Neinchel, Nayna Paryani, Amber Mottola, Eva Day, Martha Navarro

Atella Clinical Research La Palma, CA: Rafaelito Victoria, Xanthe Victoria, Rene Uong

Atrium Health, Charlotte, NC: Mindy Sampson, Christopher Polk, Michael Leonard, Lewis McCurdy, Leigh A. Medaris, Zainab Shahid, Lisa Davidson

Avera McKennan Hospital and University Health Center, Sioux Falls, SD: Jawad Nazir, John Lee, Amy Elliott, Swami Sathyanaryan, Mansi Oberoi, Muhammad (Danial) Siddiqui, Muhammad Arsad, Kara Bruning

Adolescent & Young Adult Research at Core – NIAID CoVPN, Chicago, IL: Sybil Hosek, Temitope Oyedele, Vanessa Sarda, Monica Mercon

Beth Israel Deaconess Medical Center, Boston, MA: Kathryn Stephenson, Dan Barouch, Boris Juelg, Chen Sabrina Tan, Rebecca Zash, Ai-ris Collier, Jessica Ansel, Kate Jaegle

Bio-Medical Research, LLC, Miami, FL: Lilia Roque-Guerrero, Ana Gomez Ramirez, Javier Capote, Gisel Paz

Boston Medical Center Ped. HIV Program NICHD – NIAID CoVPN, Boston, MA: Michael Paasche-Orlow, Julien Dedier

California Medical Research Associates, Northridge, CA: Sanjay Vadgama, Ramachandra Patak

Cardiology Care Clinics, Eatonton, GA: Nicolas Chronos, Cary Hefty

Carolina Institute for Clinical Research, Fayetteville, NC: Judith Borger, Ifeanyi Momodu, Lindsey Carswell, Benjamin King, Ryan Starr, Scott Syndergaard

Carolina Medical Research, Clinton, SC: Nancy Patel, Ravikumar Patel, Ryan Sattar

Catalina Research Institute, Montclair, CA: Rizwana Mohseni, Jeffrey Unger, Sheila De Jesus-Maranan, Cecilia Casaclang

Centex Studies, Lake Charles, LA: Michael Seep, Celeste Brown, Joshua Whatley

Chicago Clinical Research Institute, Chicago, IL: Dennis Levinson, Saad Alvi, Norman James, Azazuddin Ahmed

Clinical Research of Central Florida, Winter Haven, FL: Robinson Koilpillai, Stephanie Cassady, Jennifer Cox, Eduardo Torres

Clinical Trial of Florida LLC, Miami, FL: James Krainson, Mark J. Rosenthal

Crossroads Clinical Research, Corpus Christi, TX: Michael Winnie, Jerry Plemons, Omesh Verma, Richard Leggett

DM Clinical Research/BFHC Research, San Antonio, TX: Ramon Reyes, Keith Beck, Brian Poliquin

DM Clinical Research/LinQ Research, LLC, Pearland, TX: Murtaza Mussaji, Jignesh Shah

East Coast Institute for Research, Jacksonville, FL: David Sutton, Edward Pereira, Rodel Gloria, Stacey Kelly, Amy Dennis-Saltz, Mae Sheikh-Ali, Elias Saikali, James Magee, Rebecca Goldfaden

Epic Medical Research, Red Oak, TX: Haresh Boghara, Sunny Patel, Bari Eichelbaum

Excel Clinical Research, Las Vegas, NV: Duane Anderson, Sean Su, Alexander Akhavan, Diana Kirby, Joy Venglik

Fenway Health – NIAID CoVPN, Boston, MA: Kenneth Mayer, Taimur Khan, Marcy Gelman

Florida Pulmonary Research Institute, LLC, Winter Park, FL: Faisal A. Fakhri, Faisal M. Fakhri, Daniel Layish, Fernando Alvarado, Jose Diaz

Fomat Medical Research, Oxnard, CA: Augusto Focil, Griselda Rosas, Stevan Correa, Michael Bogseth

Future Innovative Treatments, LLC, Colorado Springs, CO: Bhaktasharan Patel, Gary Tarshis, Katrina Grablin

Geisinger Medical Center, Danville, PA: Paul Simonelli, Stanley Martin, Alvin Sharma, Anna Chen, Pragya Dhaubhadel, Shaeesta Khan, Sreelatha Naik, Sudheer Penupolu, Thulashie Sivarajah, Tae-Sung Kwon, Lakshmi Saladi

Geisinger Wyoming Valley, Wilkes-Barre, PA: Paul Simonelli, Stanley Martin, Alvin Sharma, Anna Chen, Pragya Dhaubhadel, Shaeesta Khan, Sreelatha Naik, Sudheer Penupolu, Thulashie Sivarajah, Tae-Sung Kwon, Lakshmi Saladi

Harlem Hospital Center – New York City Health and Hospitals Corporation, Harlem, NY: Farbod Raiszadeh, Sharon Mannheimer, Khaing Myint, Hussein Assallum, Lovelyamma Varghese, Akari Kyawa

Harlem Prevention Center – NIAID CoVPN, Harlem, NY: Ellen Morrison, Sharon Mannheimer, Julie Franks, Jun Avelino Loquere, Orlando Rosario, Andrea Low, Joan Villacruz

HD Research Group, Houston, TX: Alan Skolnick, Harold Minkowitz, David Leiman, Todd Price, Anatoli Krasko, Idisoro Wiener

Healthcare Research Network, Hazelwood, MO: Larry Reed, Oscar Lin

Henry Ford Health System, Detroit, MI: Mayur Ramesh, George Alangaden

Holy Name Medical Center, Teaneck, NJ: Suraj Saggar, Thomas Birch, Benjamin De La Rosa, Karyna Neyra, Erina Kunwar

IACT Health, Columbus, GA: Jeffrey Kingsley, April Pixler, Veronica McBride

Icahn School of Medicine at Mount Sinai, New York, NY: Judith Aberg, Michelle Cespedes, Alexandra Abrams-Downey, Erna Kojic, Luz Lugo, Sean Liu, Nadim Salomon, David Perlman, Deena Altman, Farah Rahman, Georgina Osorio, Joseph Mathew, Sanjana Koshy, Dana Mazo, Francesca Cossarini, Sondra Middleton, Alina Jen, Erika Maria Reategui Schwarz

Innovative Research of West Florida, Clearwater, FL: Miguel Trevino, Benjamin DeVries

Lincoln Medical Center – New York City Health and Hospitals Corporation, Bronx, NY: Vidya Menon, Moiz Kasubhai, Usha Venugopal, Anjana Pillai, Franscene Oulds

M3 Wake Research, Raleigh, NC: Matthew Hong, Wayne Harper, Lynn Eckert, Douglas Wadeson, Lisa Cohen

Maryland School of Medicine, Baltimore, MD: Joel Chua, Shyam Kottlil, Jennifer Husson, John Baddley, R. Gentry Wilkerson, Shivakumar Narayanan, Uzoamaka Eke, Myint Noe, Melanie Malave Sanchez

Massachusetts General Hospital – ID Clinical Research Unit – NIAID CoVPN, Boston, MA: Arthur Kim, Greg Robbins, Mark Siedner, Rajesh Gandhi, Kristen Hysell, Jacob Lazarus, Lael Yonker

McGovern Medical School at The University of Texas Health Science Center, Houston, TX: Roberto Arduino, Karen J. Vigil

Medical Research of Westchester, Miami, FL: Richard Perez-Perez, Carlos J. Bello, Esperanza Arce-Nunez, Jorge Acosta, Julio L. Arronte

Medical University of South Carolina, Charleston, SC: Eric Meissner, Patrick Flume, Andrew Goodwin, Deeksha Jandhyala, Nandita Nadig

MedPharmics, Metairie, LA: Robert Jeanfreau, Susan Jeanfreau, Susan Tortorich, Shiva Akula

MedPharmics, , Gulfport, MS: Paul Matherne, Donald Gaddy, Magdy Mikhail

Mercury Clinical Research, Houston, TX: Rajasekaran Annamalai, Huy Nguyen, Nizar Nayani, Mahalakshmi Ramchandra

META Medical Research Institute, Dayton, OH: Priyesh Mehta, Jacqueline Horne, Grace Hassan

Midland Florida Clinical Research Center, Deland, FL: Godson Oguchi, Judepatricks Onyema

Midway Immunology and Research Center, Fort Pierce, FL: Moti Ramgopal, Brenda Jacobs, Lisa Cason, Angela Trodglan

National Institute of Infectious Diseases, Bucharest, Romania: Adrian Streinu, Daniela Manolache, Anca Streinu-Cercel, Oana Sandulescu, Ana Blanaru, Monica Stoica, Ana Maria Andone, Daniela Dospinoiu, Silviu Serban, Loredana Patru, Christina Buhuara, Ramona Dorobantu, Magdalena Motoi, Ioana Daramus, George Bihoi, Alexandra Ghita, Victor Miron, Gylda Spataru

New Jersey Medical School Clinical Research Center – NIAID CoVPN, Newark, NJ: Amesika Nyaku, Shobha Swaminathan

Next Level Urgent Care, Houston, TX: Terence Chang, Robbyn Traylor, Lenee Gordon, John McDivitt, Lizette Castro

Northern California Research, Sacramento, CA: Douglas Young, Gary Carson

New York University Langone Vaccine Center – NIAID CoVPN, Manhattan, NY: Angelica Kottkamp, Mark J. Mulligan, Anna Bershteyn, Vanessa Raabe, Tamia Davis, Mary Olson

Ohio State University AIDS Clinical Trials Unit – NIAID CoVPN, Columbus, OH: Seuli Brill, Carlos Malvestutto, Susan Koletar, Taru Saigal, Mahdee Sobhanie, Vignesh Doraiswamy, Mahrous Abo Hassan, Jeremy Young

Orlando Immunology Center, Orlando, FL: Edwin DeJesus, Charlotte-Paige Rolle, Federico Hiestrosa, Dan Cruz, Terry Wilder, Jeffrey Garrett, Stephanie Skipper

Paradigm Clinical Research Institute, Torrance, CA: Ramprasad Dandillaya, Kartik Ananth

Penn Prevention – NIAID CoVPN, Philadelphia, PA: Ian Frank, Helen Koenig, Eileen Donaghy, Debora Dunbar

PMG Research of McFarland Clinic, Ames, IA: Jennifer Killion, Rupal Amin, Shauna Basener, Timothy Lowry

PMG Research of Wilmington, Wilmington, NC: Kevin Cannon, Mesha Chadwick

Qway, Hialeah, FL: Oscar Galvez, Fausto Castillo

Regional One Health, Memphis, TN: John Jefferies, Sandy Arnold, Amber Thacker

Remington-Davis, Columbus, OH: Edward Cordasco, Brian Zeno, Heather Holmes, Heather Lee

Republican Clinical Hospital, Chisinau, Moldova: Natalia Gaibu, Victor Cojocaru, Aristia Seremet, Sergiu Iacob, Rodica Usatii, Nelea Ghicavii, Angela Coltuclu, Oxana Bujor

Rhode Island Hospital, Providence, RI: Eleftherios Mylonakis, Dimitrios Farmakiotis, Karen Tashima, Natasha Ryback

Ruane Clinical Research Group, Los Angeles, CA: Peter Ruane, Peter Wolfe, Kenny Trinidad

Rush University Medical Center, Chicago, IL: James Moy, Raj Shah, Bandi Sindhura, Beverly Sha

San Francisco Research Institute, San Francisco, CA: Mark Savant, Francis Hsiao, Edna Yee

Sarasota Memorial Hospital, Sarasota, FL: Manuel Gordillo, Rishi Bhattacharyya, Sudha Tallapragada, Annette Artau, Julie Larkin, Roberto Mercado, Michael Milam, Natan Kraitman, Michael Lowry, Sarah Temple, Lenka Offner, Rabih Loutfi, Kirk Voelker, Marshall Frank, Ashley Grant

SignatureCare Emergency Center – TC Jester, Houston, TX: Alan Skolnick, Harold Minkowitz, David Leiman, Todd Price, Anatoli Krasko

St. Hope Foundation, Bellaire, TX: James Sims III, Manuel Vasquez, Kenneth Degazon, Katherine Asuncion

Stanford University, Palo Alto, CA: Jason Andrews, Aruna Subramanian, Upinder Singh, Yvonne Maldonado, Chaitan Khosla

Tandem Clinical Research, Maitland, FL: Esteban Olivera, Mayra Abreu

Tandem Clinical Research, Marrero, LA: Adil Fatakia, Marissa Miller, Kristen Clinton, Gary Reiss

The Hope Clinic of Emory University – NIAID CoVPN, Decatur, GA: Srilatha Edupuganti, Nadine Roupheal, Colleen Kelley, Varun Phadke, Cassie Grimsley Ackerley, Matthew Collins

The Lundquist Institute, Torrance, CA: Loren Miller, Timothy Hatlen

The Ponce de Leon Center Clinical Research Site – NIAID CoVPN, Atlanta, GA: Michael Chung, Colleen Kelley, Valeria Cantos Lucio, Carlos del Rio, Jeffrey Lennox, Sheetal Kandiah, Caitlin Moran, Anandi Sheth, Paulina Rebolledo, Nithin Gopalsamy, Divya Bhamidipati

Triple O Research Institute PA, West Palm Beach, FL: Olayemi Osiyemi, Jose A. Menajovsky-Chaves, Christina Campbell

Tufts Medical Center, Boston, MA: Andrew Strand, Andreas Klein, Debra Poutsiaka, Roberto Viau Colindres, Brian Chow, Cheleste Thorpe, Mary Hopkins, Jenn Chow, Rakhi Kohli, Jose Caro, Jeffrey Griffiths, Helen Boucher, Whitney Perry, Laura Kogelman, Yoav Golan, Tine Vindenes, Carlos Mendoza, Saba Mostafavi, Christian Alejandro Cano Guerra, Paula Dabenigno, Bipin Malla

Tulane University School of Medicine, New Orleans, LA: Dahlene Fusco, Arnaud Drouin, Joshua Denson, Jerry Zifodya, Christine Bojanowski, Monika Dietrich, Stacy Drury

University of Illinois at Chicago Project WISH – NIAID CoVPN, Chicago, IL: Jesica Herrick, Richard Novak, Mahesh Patel

Universal Medical and Research Center, LLC, Miami, FL: Gerard Acloque, Agustin Martinez

University at Buffalo, State University of New York, Buffalo, NY: Sanjay Sethi, Brian Clemency, Rajesh Kunadharaju

University of Arizona, Tucson, AZ: Sairam Parthasarathy, Franz Rischard

University of California Davis, Sacramento, CA: Stuart Cohen, George Thompson, Hien Nguyen, Scott Crabtree

University of Cincinnati, Cincinnati, OH: Carl Fichtenbaum, Moises Huaman, Jaime Robertson

University of Colorado School of Medicine, Aurora, CO: Eric Simoes, Thomas Campbell, Poornima Ramanan, Hillary Dunlevy, Esther Benamu, Amiran Baduashvili, Martin Krsak, Steven Johnson, Lakshmi Chauhan, Erica Fredregil, Samantha Economos

University of Miami – Miller School of Medicine, Miami, FL: Gary Kleiner, Lilian Abbo, Bhavarth Shukla, Jennifer Gebbia, Maria Rodriguez

University of Minnesota, Minneapolis, MN: Anne-Marie Leuck, Mahsa Abassi, Matthew Pullen

University of Mississippi, Jackson, MS: Jose Lucar Lloveras, Leandro Mena, Luis Shimose Ciudad

University of North Carolina, Chapel Hill, NC: Jessica Lin, David Wohl, Christopher Hurt, William Fischer II, Kathleen Tompkins

University of South Florida, Tampa, FL: Kami Kim, Seetha Lakshmi, Charurut Somboonwit, Jason Wilson, Asa Oxner, Tiffany Vasey, Lucy Guerra

University of Virginia, Charlottesville, VA: William Petri, Katie Dykstra, Marianne Morrissey, Lejla Cesko, Jae Shin, Cirle Warren, Jennifer Sasson, Chelsea Marie, Debbie-Ann Shirley, Rebecca Carpenter, Gregory Madden, Danielle Donigan, Michelle

Sutton, Cynthia Edwards, Elizabeth Brooks, Rebecca Wade, Samantha Simmons,
Jennifer Pinnata

University of Washington Medical Center, Seattle, WA: Ruanne Barnabas, Shelly
Karuna, Ann C. Collier, Julie McElrath, Janine Maenza, Adrienne Shapiro, Helen
Stankiewicz-Karita, Helen Chu, Chandler Church

University of Wisconsin, Madison, WI: William Hartman, Joseph Connor, Robert
Striker

University of Texas Health Science Center, Tyler, TX: Julie Philley, Megan Devine,
Richard Yates, Steven Hickerson

Vanderbilt Vaccine Clinical Research Site – NIAID CoVPN, Nashville, TN: Spyros
Kalams, Greg Wilson

Virginia Commonwealth University School of Medicine, Richmond, VA: Michael
Donnenberg, Marjolein de Wit

VitaLink Research, Gaffney, SC: David Erb, Luis DeLaCruz, Supinder Channa

Whitman-Walker Health – NIAID CoVPN, Washington, DC: Sarah Henn, Megan
Coleman, Lynsay MacLaren, Deborah Goldstein, Alice Eggleston, Carrington Koebele

WR-ClinSearch, LLC, Chattanooga, TN: Mark McKenzie, Teresa Deese

WR-Mount Vernon Clinical Research, LLC, Sandy Springs, GA: Benjamin Thomas,
Laura Tsakiris, Stephen Blank, Ronald Mirenda

Xera Med Research, Boca Raton, FL: Anna Martin, Gargi Gharat, Candace Kokaram,
Ket Wray, Clement Partap, Ulyana Arzamasova, Kristina Louissaint, Maria Fernandez

Xera Med Research, Miami, FL: Anna Martin, Ket Wray, Kristina Louissaint, Maria
Fernandez, Gargi Gharat

Regeneron Study Team

Achint Chani, Adebisi Adepaju, Adnan Mahmood, Aisha Mortagy, Ajla Dupljak, Alina Baum, Alison Brown, Amy Froment, Andrea Hooper, Andrea Margiotta, Andrew Bombardier, Anita Islam, Anne Smith, Arvinder Dhillon, Audra McMillian, Aurora Breazna, Ayesha Aslam, Barabara Carpentino, Bari Kowal, Barry Siliverstein, Benjamin Horel, Bo Zhu, Bret Musser, Brian Bush, Brian Head, Brian Snow, Bryan Zhu, Camille Debray, Careta Phillips, Carmella Simiele, Carol Lee, Carolyn Nienstedt, Caryn Trbovic, Casey (Kuo-Chen) Chan, Catherine Elliott, Chad Fish, Charlie Ni, Christa Polidori, Christine Enciso, Christopher Caira, Christopher Powell, Christos A. Kyratsous, Cliff Baum, Colin McDonald, Cynthia Leigh, Cynthia Pan, Dana Wolken, Danielle Manganello, David Liu, David Stein, David M. Weinreich, Dawlat Hassan, Daya Gulabani, Deborah Fix, Deborah Leonard, Deepshree Sarda, Denise Bonhomme, Denise Kennedy, Devin Darcy, Dhanalakshmi Barron, Diana Hughes, Diana Rofail, Dipinder Kaur, Divya Ramesh, Dona Bianco, Donna Cohen, Eduardo Forleo Neto, Edward Jean-Baptiste, Ehsan Bukhari, Eileen Doyle, Elizabeth Bucknam, Emily Labriola-Tomkins, Emily Nanna, Esther Huffman O'Keefe, Evelyn Gasparino, Evonne Fung, Flonza Isa, Fung-Yee To, Gary Herman, George D. Yancopoulos, Georgia Bellingham, Giane Sumner, Grainne Moggan, Grainne Power, Haixia Zeng, Hazel Mariveles, Heath Gonzalez, Helen Kang, Hibo Noor, Ian Minns, Ingeborg Heirman, Izabella Peszek, James Donohue, Jamie Rusconi, Janice Austin, Janie Parrino, Jeannie Yo, Jenna McDonnell, Jennifer D. Hamilton, Jessica Boarder, Jianguo Wei, Jingchun Yu, Joanne Malia, Joanne Tucciarone, Jodie Tyler-Gale, John D. Davis, John Strein, Jonathan Cohen, Jonathan Meyer, Jordan Ursino, Joseph Im, Joseph Tramaglino,

Joseph Wolken, Kaitlyn Potter, Kaitlyn Scacalossi, Kamala Naidu, Karen Browning, Karen Rutkowski, Karen Yau, Katherine Woloshin, Kelly Lewis-Amezcuca, Kenneth Turner, Kimberly Dornheim, Kit Chiu, Kosalai Mohan, Kristina McGuire, Kristy Macchi, Kurt Ringleben, Kusha Mohammadi, Kyle Foster, Latora Knighton, Leah Lipsich, Lindsay Darling, Lisa Boersma, Lisa Cowen, Lisa Hersh, Lisa Jackson, Lisa Purcell, Lisa Sherpinsky, Livia Lai, Lori Faria, Lori Geissler, Louise Boppert, Lyra Fiske, Marc Dickens, Marco Mancini, Maria C. Leigh, Meagan O'Brien, Michael Batchelder, Michael Klinger, Michael Partridge, Michel Tarabocchia, Michelle Wong, , Mivianisse Rodriguez, Moetaz Albizem, Muriel O'Byrne, Ned Braunstein, Neena Sarkar, Neil Stahl, Nicole Deitz, Nicole Memblatt, Nirav Shah, Nitin Kumar, Olga Herrera, Oluchi Adedoyin, Ori Yellin, Pamela Snodgrass, Patrick Floody, Paul D'Ambrosio, Paul (Xiaobang) Gao, Peijie Hou, Philippa Hearld, Qin Li, Rachel Kitchenoff, Rakiyya Ali, Ramya Iyer, Ravikanth Chava, Rinol Alaj, Rita Pedraza, Robert Hamlin, Romana Hosain, Ruchin Gorawala, Ryan White, Ryan Yu, Rylee Fogarty, S. Balachandra Dass, Sagarika Bollini, Samit Ganguly, Sandra DeCicco, Sanket Patel, Sarah Cassimaty, Selin Somersan-Karakaya, Shane McCarthy, Sharon Henkel, Shazia Ali, Shelley Geila Shapiro, Somang Kim, Soraya Nossoughi, Stephanie Bisulco, Steven Elkin, Steven Long, Sumathi Sivapalasingam, Susan Irvin, Susan Wilt, Tami Min, Tatiana Constant, Theresa Devins, Thomas DiCioccio, Thomas Norton, Travis Bernardo, Tzu-Chien Chuang, Victor (Jianguo) Wei, Vinh Nuce, Vishnu Battini, Wilson Caldwell, Xiaobang Gao, Xin Chen, Yanmei Tian, Yasmin Khan, Yuming Zhao, Yunji Kim

NIAID/CoVPN Team

Bonnie Dye (CoVPN), Christopher B. Hurt (CoVPN), Dale R. Burwen (NIAID), Dan H. Barouch (CoVPN), David Burns (NIAID), Elizabeth Brown (CoVPN), Katharine J. Bar (CoVPN), Mary Marovich (NIAID), Meredith Clement (CoVPN), Myron S. Cohen (CoVPN), Nirupama Sista (CoVPN), Ruanne V. Barnabas (CoVPN), Sheryl Zwierski (NIAID)

Supplementary Methods

Trial Oversight

Regeneron designed the trial in collaboration with CoVPN/NIAID and gathered the data with the trial investigators. The investigators, site personnel, CoVPN/NIAID, and Regeneron were unaware of the treatment-group assignments. Regeneron analyzed the data. A Data and Safety Monitoring Board convened by the National Institutes of Health evaluated safety data to make recommendations for trial modification and/or termination.

The central or local institutional review board or ethics committee at each study center oversaw trial conduct and documentation. All participants provided written informed consent before participating in the trial.

Stratification

Assignment of treatment group (1200 mg REGEN-COV or placebo) was stratified by the following prior to randomization:

1. Test results (positive, negative, or undetermined) of a local diagnostic assay for SARS-CoV-2 (e.g., molecular assay such as RT-PCR assay for SARS-CoV-2 or a SARS-CoV-2 antigen test) from appropriate samples (e.g., nasopharyngeal, oropharyngeal, nasal, or saliva)
2. Age:
 - ≥ 12 and < 18 years
 - ≥ 18 and < 50 years
 - ≥ 50 years

Inclusion and Exclusion Criteria

Inclusion criteria:

A participant must meet the following criteria to be eligible for inclusion in the study:

1. Adult participants 18 years of age (irrespective of weight) and above at the signing of informed consent or adolescent participants ≥ 12 to < 18 years of age, or pediatric participants < 12 years of age at the signing of the assent (parent/guardian sign the informed consent)
2. Asymptomatic household contact with exposure to an individual with a diagnosis of SARS-CoV-2 infection (index case). To be included in the study, participants must be randomized within 96 hours of collection of the index cases' positive SARS-COV-2 diagnostic test sample
3. Participant anticipates living in the same household with the index case until study day 29
4. Is judged by the investigator to be in good health based on medical history and physical examination at screening/baseline, including participants who are healthy or have a chronic, stable medical condition
5. Willing and able to comply with study visits and study-related procedures/assessments
6. Provide informed consent signed by study participant or legally acceptable representative

Exclusion criteria:

A participant who meets any of the following criteria will be excluded from the study:

1. Participant-reported history of prior positive SARS-CoV-2 RT-PCR test or positive SARS CoV-2 serology test at any time before the screening
2. Participant has lived with individuals who have had previous SARS-CoV-2 infection or currently lives with individuals who have SARS-CoV-2 infection, with the exception of the index case(s), the first individual(s) known to be infected in the household
3. Active respiratory or non-respiratory symptoms consistent with Covid-19
4. History of respiratory illness with sign/symptoms of SARS-CoV-2 infection, in the opinion of the investigator, within the prior 6 months to screening
5. Nursing home resident
6. Any physical examination findings, and/or history of any illness, concomitant medications or recent live vaccines that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the participant by their participation in the study
7. Current hospitalization or was hospitalized (i.e., >24 hours) for any reason within 30 days of the screening visit
8. Has a history of significant multiple and/or severe allergies (e.g., latex gloves), or has had an anaphylactic reaction to prescription or non-prescription drugs or food. This is to avoid possible confounding of the safety analysis and not due to any presumed increased risk of these individuals to a reaction to the investigational product
9. Treatment with another investigational agent in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer, prior to the screening visit

10. Received an investigational or approved SARS-CoV-2 vaccine
11. Received investigational or approved passive antibodies for SARS-CoV-2 infection prophylaxis (e.g., convalescent plasma or sera, monoclonal antibodies, hyperimmune globulin)
12. Use of hydroxychloroquine/chloroquine for prophylaxis/treatment of SARS-CoV-2 or anti-SARS-viral agents*, e.g., remdesivir, within 60 days of screening
* Hydroxychloroquine/chloroquine for other uses, e.g., for use in autoimmune diseases is allowed
13. Member of the clinical site study team and/or immediate family
14. Exclusion criterion #14 excluding sexually active men who are unwilling to use the following forms of medically acceptable birth control during the study drug follow-up period and for 8 months after single dose of study drug was removed since enrollment was expanded to include all women in protocol amendment 4.
15. Exclusion criterion #15 excluding pregnant or breastfeeding women was removed since enrollment was expanded to all women in protocol amendment 4.
16. Exclusion criterion #16 excluding women of childbearing potential (WOCBP)* and girls at or beyond menarche (≥ 12 to < 18 years of age) who were unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 8 months after the last dose was removed since enrollment was expanded to all women in protocol amendment 4.

* WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization

methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.

Covid-19 Signs and Symptoms – Broad-Term, Strict-Term, and CDC Definitions

Broad-Term

Fever $\geq 38^{\circ}\text{C}$

The signs and symptoms below:

1. Feverish
2. Sore throat
3. Cough
4. Shortness of breath/difficulty breathing (*nasal flaring**)
5. Chills
6. Nausea
7. Vomiting
8. Diarrhea
9. Headache
10. Red or watery eyes (*conjunctivitis*)
11. Body aches such as muscle pain or joint pain (*myalgia, arthralgia*)
12. Loss of taste/smell
13. Fatigue (*fatigue or general malaise or lethargy**)
14. Loss of appetite or poor eating/feeding
15. Confusion
16. Dizziness
17. Pressure/tightness in chest
18. Chest pain

19. Stomach ache (abdominal pain*)

20. Rash

21. Sneezing

22. Runny nose

23. Sputum/phlegm

Other

**Signs and symptoms observed in pediatric participants*

Strict-Term

Fever ($\geq 38^{\circ}\text{C}$) PLUS ≥ 1 respiratory symptom (sore throat, cough, shortness of breath)

OR

2 respiratory symptoms (sore throat, cough, shortness of breath)

OR

1 respiratory symptom (sore throat, cough, shortness of breath) PLUS ≥ 2 non-respiratory symptoms (chills, nausea, vomiting, diarrhea, headache, conjunctivitis, myalgia, arthralgia, loss of taste or smell, fatigue or general malaise)

CDC Definition

<https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>

At least 2 of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, nausea or vomiting, diarrhea, fatigue, congestion or runny nose

OR

Any 1 of the following symptoms: cough, shortness of breath, difficulty breathing, new olfactory disorder, new taste disorder

OR

Severe respiratory illness with at least 1 of the following, clinical or radiographic evidence of pneumonia, ARDS.

Pharmacokinetic Analysis Methods

Bioanalytical Methods

The concentrations of REGN10933 (casirivimab) and REGN10987 (imdevimab) in human serum were measured using validated immunoassays which employ streptavidin microplates from Meso Scale Discovery (MSD, Gaithersburg, MD, USA). The methods utilized two anti-idiotypic monoclonal antibodies, each specific for either REGN10933 or REGN10987, as the capture antibodies. Captured REGN10933 and REGN10987 were detected using two different, non-competing anti-idiotypic monoclonal antibodies, each also specific for either REGN10933 or REGN10987. The bioanalytical methods specifically quantified the concentrations of each anti-SARS-CoV-2 spike monoclonal antibody separately, with no interference from the other antibody. The assay has a lower limit of quantification (LLOQ) of 0.156 mg/L for each analyte in the undiluted serum sample.

Pharmacokinetic Methods

The pharmacokinetics (PK) analysis population included all participants who received active study drug (safety population) and who had at least 1 non-missing result following the first dose of study drug. Participants were analyzed based on actual treatment received. For the sentinel group of Part B, 4 participants were included in the PK analysis set. For the safety group of Part B, 9 participants were included in the PK analysis set. Overall, the PK analysis set is comprised of 13 participants.

Blood samples for measurement of casirivimab and imdevimab concentrations in serum were collected from participants randomized to 1200 mg SC or placebo in the sentinel group of Part B at predose, and on Days 2, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 197, and 225. Blood samples for drug concentration also were collected from participants randomized to 1200 mg or placebo in the safety group of Part B at predose, and on Days 29, 57, 113, 169, and 225.

From the above drug concentration blood sampling schedule, PK parameters were determined by non-compartmental methods (Gibaldi 1982) using Phoenix WinNonlin (version 8.3 Certara, L.P.). Area Under the Curve in serum from Day 0 to 28 (AUC_{0-28}) was determined using the log-linear trapezoidal rule and actual sample collection times. Area Under the Curve from time zero extrapolated to infinite time (AUC_{inf}) was determined as AUC through the last measurable concentration (C_{last}) + C_{last}/λ_z , where λ_z is the slope of the terminal phase of the concentration-time curve. C_{max} was determined as the maximum observed concentration in serum and t_{max} is the time of maximal concentration in serum. Terminal half-life ($t_{1/2}$) was estimated as $0.693/\lambda_z$, using actual times.

Additional Statistical Methods

Hierarchical Testing Sequence

Hierarchy*	Description
Primary	Proportion of participants who subsequently develop signs and symptoms (broad-term) within 14 days of a positive RT-qPCR at baseline or during the efficacy assessment period
Key Secondary	Number of weeks of symptomatic SARS-CoV-2 infection (broad-term) within 14 days of a positive RT-qPCR at baseline or during the efficacy assessment period
Key Secondary	Number of weeks of high viral load >4 (log ₁₀ copies/mL) in nasopharyngeal swab samples during the efficacy assessment period

* If statistical significance is established for the primary efficacy endpoint, a hierarchical testing procedure will be applied to the key secondary endpoints at a 2-sided 0.05 significance level. The order of testing sequence for key secondary endpoints is provided in the table.

RT-qPCR, quantitative reverse transcription polymerase chain reaction.

Endpoint Analyses

The primary efficacy endpoint was analyzed using logistic regression as the proportion of households with only a single study participant in the seronegative mFAS-B population was more than 80%. The model included fixed category effects of treatment group (placebo vs. REGEN-COV), region (US vs. ex-US), and age (≥ 12 to < 50 years of age vs. ≥ 50 years of age).

The key secondary efficacy endpoints were analyzed by Van Elteren tests stratified by region and age.

Calculation of Number of Weeks

The duration of symptomatic infection (weeks) is defined as: (the end date of all symptoms minus the date of the first symptom+1)/7. If the symptom is ongoing at the time of the analysis, the end date will be set as the cutoff date for the analysis.

The duration of high viral load (weeks) is calculated by counting the nominal visit weeks during the efficacy assessment period with a high viral load of $>4 \log_{10}$ copies/ml.

Missing Data

Participants with Covid-19 symptoms who are missing a central lab-determined RT-qPCR test during the efficacy assessment period (eg. are too sick to go to the study site) but have a positive SARS-CoV-2 test from a local lab (eg. in the hospital) are considered to have a symptomatic infection if any of the signs and symptoms of Covid-19 occurred within 14 days of the positive SARS-CoV-2 test observed during the efficacy assessment period.


For virologic endpoints, if nasopharyngeal (NP) swab viral load data is missing for a visit, it is not imputed. Only non-missing available NP swab viral load data are used for the analysis of viral load endpoints. Only participants with at least one post-baseline viral load data point (in NP swab samples) are included in the analysis.

Supplementary Figures

Figure S1. Schematic Overview of the Study Design

Eligible participants:


- Age criterion: adults (≥ 18 years of age), adolescents (≥ 12 and < 18 years of age), and pediatrics (< 12 years of age)*
- Asymptomatic household contact with exposure to an individual with a diagnosis of SARS-CoV-2 infection (index case)
- Randomized within 96 hours of collection of the index case's positive test sample
- Baseline RT-qPCR test to determine if in Cohort A (RT-qPCR negative) or Cohort B (RT-qPCR positive) for data analysis



*Pediatric participants are not included in the presented analysis.

Covid-19, coronavirus disease 2019; D, day; EAP, efficacy assessment period; RT-qPCR, quantitative reverse transcription polymerase chain reaction; SC, subcutaneous.

Figure S2. Flow Diagram for the Analysis Population




*Excludes the 554 participants from a previous interim analysis.

†Seronegative: negative result on all available anti-SARS-CoV-2 antibody tests (ie, no evidence of prior infection); seropositive: positive result on one or more available anti-SARS-CoV-2 antibody tests; sero-undetermined: borderline result on one or more available anti-SARS-CoV-2 antibody tests.

‡This is the seronegative mFAS-B population. Among this population, 3 participants (2 in the placebo group and 1 in the REGEN-COV group) were determined post-randomization to have symptomatic disease at baseline and were excluded from the efficacy analyses.

EAP, efficacy assessment period; mFAS-B, modified full analysis set B; RT-qPCR, quantitative reverse transcription polymerase chain reaction.

Figure S3. Mean Viral Load in Symptomatic and Asymptomatic SARS-CoV-2 PCR+ Individuals




*Outpatients (Study 2067): symptomatic, RT-qPCR positive, seronegative at baseline; LS mean difference (MMRM) between REGEN-COV and placebo at Day 8: -0.93 log₁₀ copies/ml.

†Early treatment (Study 2069-B): asymptomatic, RT-qPCR positive, seronegative at baseline; LS mean difference (ANCOVA) between REGEN-COV and placebo at Day 8: -1.5 log₁₀ copies/ml.

ANCOVA, analysis of covariance; IV, intravenous(ly); LS, least squares; MMRM, mixed model repeated measures; PCR, polymerase chain reaction; RT-qPCR, reverse transcription quantitative polymerase chain reaction; SC, subcutaneous, SE, standard error.


Figure S4. Viral Load Over Time in the Placebo Arm by Baseline Serology Status



No. of patients:	Baseline	8	15	22	29
Serum Antibody-Negative	100	99	97	92	95
Serum Antibody-Positive	37	36	37	36	32


LLOQ, lower limit of quantitation; SE, standard error.

Figure S5. Mean (+SD) Concentrations of REGN10933 and REGN10987 in Serum Over Time (Part B Sentinel Group)



SC, subcutaneous, SD, standard deviation.

Figure S6. Mean (+SD) Concentrations of REGN10933 and REGN10987 in Serum Over Time (Part B Sentinel + Safety Group)



SC, subcutaneous, SD, standard deviation.

Supplementary Tables

Table S1. Demographics and Baseline Characteristics (Seropositive)

	Placebo (N=38)	REGEN-COV 1200 mg SC (N=46)	Total (N=84)
Age — yr			
Mean (SD)	39.1 (16.6)	40.0 (17.9)	39.6 (17.2)
≥50 — no. (%)	10 (26.3)	18 (39.1)	28 (33.3)
Male sex — no. (%)	21 (55.3)	26 (56.5)	47 (56.0)
Race — no. (%)			
White	30 (78.9)	43 (93.5)	73 (86.9)
Black or African American	5 (13.2)	0	5 (6.0)
Asian	2 (5.3)	2 (4.3)	4 (4.8)
American Indian or Alaska Native	0	0	0
Other	1 (2.6)	1 (2.2)	2 (2.4)
Ethnicity — no. (%)			
Hispanic or Latino	17 (44.7)	26 (56.5)	43 (51.2)
Not Hispanic or Latino	20 (52.6)	20 (43.5)	40 (47.6)
Other	1 (2.6)	0	1 (1.2)
Weight — kg, mean (SD)	79.8 (19.2)	82.6 (18.8)	81.4 (18.9)
BMI*			
Mean (SD)	27.7 (5.6)	28.5 (5.5)	28.1 (5.5)
>30 — no. (%)	8 (21.1)	17 (37.0)	25 (29.8)
Participants with any high-risk factor for Covid-19 — no. (%)	11 (28.9)	11 (23.9)	22 (26.2)
≥65 years of age	5 (13.2)	5 (10.9)	10 (11.9)
BMI* ≥35 kg/m ²	4 (10.5)	5 (10.9)	9 (10.7)
Chronic kidney disease	0	0	0
Diabetes	2 (5.3)	2 (4.3)	4 (4.8)
Immunosuppressive disease	0	0	0
Receiving immunosuppressive treatment	0	1 (2.2)	1 (1.2)
≥55 years of age with CVD, hypertension, or COPD	3 (7.9)	4 (8.7)	7 (8.3)
Total number of households	36	44	77
Number of households by size† — no. (%)‡			
1	33 (91.7)	39 (88.6)	72 (93.5)
2	1 (2.8)	3 (6.8)	3 (3.9)
3	2 (5.6)	2 (4.5)	2 (2.6)

>3

0

0

0

*The body-mass index is the weight in kilograms divided by the square of the height in meters.

†Household size is calculated by counting the seronegative mFAS-B study participants living in the same household.

‡Percentages based on the total number of households: placebo (n=36), REGEN-COV (n=44), and total (n=77).

BMI, body-mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; mFAS-B, modified full analysis set-B; SC, subcutaneous; SD, standard deviation.

Table S2. Proportion of Participants Who Had a Symptomatic RT-qPCR-Confirmed SARS-CoV-2 Infection (Broad-Term) by Period (Seronegative)

Period	Placebo n/N (%)	REGEN-COV 1200 mg SC n/N (%)	Relative Risk Reduction, %	P-value*
EAP (all participants)	44/104 (42.3)	29/100 (29.0)	31.5	0.0380
Day 4 and beyond (after Day 3)	22/104 (21.2)	5/100 (5.0)	76.4	0.0010†

*Based on logistic regression model adjusted by region (US vs ex-US) and age group (12 to <50 vs ≥50 years of age)

†Nominal

EAP, efficacy assessment period; SC, subcutaneous.

Table S3. Proportion of Participants Who Had a Symptomatic RT-qPCR-confirmed SARS-CoV-2 Infection by Definition (Seronegative)

	Placebo (N=104)	REGEN-COV 1200 mg SC (N=100)
Proportion of participants who subsequently develop signs and symptoms (broad-term) within 14 days of a positive RT-qPCR at baseline or during the EAP*		
n/N (%)	44/104 (42.3)	29/100 (29.0)
Relative risk reduction	-	31.5%
Odds ratio (95% CI)†	-	0.54 (0.298, 0.966)
P-value‡	-	0.0380
Proportion of participants who subsequently develop signs and symptoms (CDC definition) within 14 days of a positive RT-qPCR at baseline or during the EAP		
n/N (%)	41/104 (39.4)	27/100 (27.0)
Relative risk reduction	-	31.5%
Odds ratio (95% CI)†	-	0.54 (0.299, 0.989)
Proportion of participants who subsequently develop signs and symptoms (strict-term) within 14 days of a positive RT-qPCR at baseline or during the EAP		
n/N (%)	20/104 (19.2)	10/100 (10.0)
Relative risk reduction	-	48.0%
Odds ratio (95% CI)†	-	0.47 (0.207, 1.070)

*Primary endpoint

†Based on the logistic regression model adjusted by region (US vs ex-US) and age group (12 to <50 vs ≥50 years of age).

CDC, Centers for Disease Control and Prevention; CI, confidence interval; EAP, efficacy assessment period; RT-qPCR, reverse transcription quantitative polymerase chain reaction; SC, subcutaneous.

Table S4: Summary of Viral Load Endpoints (Seronegative)*

	Placebo	REGEN-COV 1200 mg SC
Baseline viral load		
n	97	95
Mean (SD)	6.2 (2.2)	6.3 (1.9)
Change in viral load (log ₁₀ copies/mL) from baseline to day 8 visits in NP swab samples		
n	97	95
Mean (SD)	-1.5 (0.2)	-3.0 (0.2)
LS mean difference (SE) vs placebo [95% CI]‡	-	-1.5 (0.3) [-2.1 to -0.8]
Change in viral load (log ₁₀ copies/mL) from baseline to day 15 visits in NP swab samples		
n	97	95
Mean (SD)	-4.0 (0.2)	-4.9 (0.2)
LS mean difference (SE) vs placebo [95% CI]‡	-	-0.9 (0.3) [-1.4 to -0.3]
Time-weighted average change from baseline in viral load (log ₁₀ copies/mL) in NP swab samples until the day 22 visit		
n	96	95
Mean (SD)	-2.5 (2.3)	-3.7 (1.7)
LS mean difference (SE) vs placebo [95% CI]‡	-	-0.9 (0.2) [-1.3 to -0.6]
Maximum (post-baseline) SARS-CoV-2 RT-qPCR viral load (log ₁₀ copies/mL) in NP swab samples during the EAP		
n	101	98
Mean (SD)	4.7 (2.6)	3.3 (2.2)
LS mean difference (SE) vs placebo [95% CI]‡		-1.4 (0.3) [-2.1 to -0.7]
Area under the curve in SARS-CoV-2 RT-qPCR viral load (log ₁₀ copies/mL·day) in NP swab samples from baseline to the first confirmed negative test		
n	82	87
Mean (SD)	81.7 (50.3)	56.4 (33.6)
LS mean difference (SE) vs placebo [95% CI]‡		-26.0 (6.0) [-38.0 to -14.1]

*Only participants with at least one post-baseline viral load data point (in NP swab samples) are included in the analysis.

‡LS means and SE taken from the ANCOVA method with the fixed categorical effects of treatment group, age group (age in years: ≥12 to <50 and ≥50), region (US vs ex-US) and the relevant baseline values as covariate as well as treatment-by-covariate interaction.

‡LS means and SE taken from the ANCOVA method with the fixed categorical effects of treatment group, age group (age in years: ≥12 to <50 and ≥50), region (US vs ex-US) and the relevant baseline values as covariate as well as treatment-by-covariate interaction.

ANCOVA, analysis of covariance; CI, confidence interval; IQR, interquartile range; LS, least-squares; NP, nasopharyngeal; RT-qPCR, quantitative reverse transcription polymerase chain reaction; SC, subcutaneous; SD, standard deviation; SE, standard error.

Table S5. Proportion of Participants Who Had a Covid-19-related Hospitalization or ER Visit (Seronegative)

	Placebo (N=104)	REGEN-COV 1200 mg SC (N=100)
Proportion of participants who had a Covid-19-related hospitalization or ER visit		
n/N (%)	6/104 (5.8)	0/100
Relative risk reduction	-	100.0%

ER, emergency room; SC, subcutaneous.

Table S6. Proportion of Participants Who Had a Symptomatic RT-qPCR-Confirmed SARS-CoV-2 Infection (Broad-Term) by Baseline Serology Status

	Placebo	REGEN-COV 1200 mg SC
Seronegative*		
n/N (%)	44/104 (42.3)	29/100 (29.0)
Relative risk reduction	-	31.5%
Odds ratio (95% CI)†	-	0.54 (0.298, 0.966)
P-value†	-	0.0380
Seropositive		
n/N (%)	5/38 (13.2)	4/46 (8.7)
Relative risk reduction	-	33.9%
Odds ratio (95% CI)†	-	0.62 (0.147, 2.587)
Seronegative, seropositive, and sero-undetermined		
n/N (%)	53/156 (34.0)	34/155 (21.9)
Relative risk reduction	-	35.4%
Odds ratio (95% CI)†	-	0.54 (0.325, 0.894)

*Primary endpoint

†Based on the logistic regression model adjusted by region (US vs ex-US) and age group (12 to <50 vs ≥50 years of age).

CI, confidence interval; SC, subcutaneous.

Table S7. Number of Weeks of Symptomatic SARS-CoV-2 Infection (Broad-Term) by Baseline Serology Status

	Placebo	REGEN-COV 1200 mg SC
Seronegative*		
n	104	100
Total, weeks	170.3	89.6
Total per 1000 participants, weeks	1637.4	895.7
Reduction†	-	45.3%
P-value‡	-	0.0273
Per-symptomatic participant, mean (SD), weeks	3.9 (4.5)	3.1 (4.1)
Per-participant, mean (SD), weeks	1.6 (3.5)	0.9 (2.6)
Seropositive		
n	38	46
Total, weeks	30.4	9.9
Total per 1000 participants, weeks	800.8	214.3
Reduction†	-	73.2%
Per-symptomatic participant, mean (SD), weeks	6.1 (9.3)	2.5 (3.4)
Per-participant, mean (SD), weeks	0.8 (3.7)	0.2 (1.1)
Seronegative, seropositive, and sero-undetermined		
n	156	155
Total, weeks	206.3	101.7
Total per 1000 participants, weeks	1322.3	656.2
Reduction†	-	50.4%
Per-symptomatic participant, mean (SD), weeks	3.9 (5.0)	3.0 (3.9)
Per-participant, mean (SD), weeks	1.3 (3.4)	0.7 (2.2)

*Key secondary efficacy endpoint

†Based on the normalized weeks per 1000 participants.

‡Based on a stratified Wilcoxon rank sum test (Van Elteren Test) with the strata region (US vs ex-US) and age group (age in years: ≥12 to <50 and ≥50).

SC, subcutaneous; SD, standard deviation.

Table S8. Number of Weeks of High Viral Load (>4 log₁₀ copies/mL) in Nasopharyngeal Swab Samples by Baseline Serology Status

	Placebo	REGEN-COV 1200 mg SC
Seronegative*		
n†	101	98
Total, weeks	82	48
Total per 1000 participants, weeks	811.9	489.8
Reduction‡	-	39.7%
P-value§	-	0.0010
Per-participant, mean (SD), weeks	0.8 (0.8)	0.5 (0.7)
Seropositive		
n†	37	45
Total, weeks	6	5
Total per 1000 participants, weeks	162.2	111.1
Reduction‡	-	31.5%
Per-participant, mean (SD), weeks	0.2 (0.4)	0.1 (0.4)
Seronegative, seropositive, and sero-undetermined		
n†	151	152
Total, weeks	97	57
Total per 1000 participants, weeks	642.4	375.0
Reduction‡	-	41.6%
Per-participant, mean (SD), weeks	0.6 (0.7)	0.4 (0.6)

*Key secondary efficacy endpoint

†Only participants with at least one post-baseline viral load data point (in NP swab samples) are included in the analysis.

‡Based on the normalized weeks per 1000 participants.

§Based on a stratified Wilcoxon rank sum test (Van Elteren Test) with the strata region (US vs ex-US) and age group (age in years: ≥12 to <50 and ≥50).

SC, subcutaneous; SD, standard deviation.

Table S9. Maximum SARS-CoV-2 RT-qPCR Viral Load (log₁₀ copies/mL) in Nasopharyngeal Swab Samples by Baseline Serology Status

	Placebo	REGEN-COV 1200 mg SC
Seronegative*		
n	101	98
LS mean (SE)	4.7 (0.2)	3.3 (0.2)
LS mean difference (SE) vs placebo	-	-1.4 (0.3)
95% CI	-	-2.1, -0.7
Mean (SD)	4.7 (2.6)	3.3 (2.2)
Median (IQR)	5.1 (3.4 : 6.3)	3.6 (2.6 : 4.9)
Seropositive*		
n	37	45
LS mean (SE)	2.3 (0.3)	2.3 (0.2)
LS mean difference (SE) vs placebo	-	0.03 (0.3)
95% CI	-	-0.6, 0.7
Mean (SD)	2.2 (2.1)	2.4 (1.6)
Median (IQR)	2.6 (0.0 : 3.7)	3.0 (0.0 : 3.6)
Seronegative, seropositive, and sero-undetermined*		
n	151	152
LS mean (SE)	4.1 (0.2)	3.0 (0.2)
LS mean difference (SE) vs placebo	-	-1.0 (0.3)
95% CI	-	-1.6, -0.5
Mean (SD)	4.1 (2.6)	3.0 (2.1)
Median (IQR)	4.0 (2.6 : 6.0)	3.3 (0.0 : 4.4)

*Only participants with at least one post-baseline viral load data point (in NP swab samples) are included in the analysis. LS means and SE taken from the ANCOVA method with the fixed categorical effects of treatment group, age group (age in years: ≥ 12 to < 50 and ≥ 50), region (US vs ex-US) and the relevant baseline values as covariate as well as treatment-by-covariate interaction.

ANCOVA, analysis of covariance; CI, confidence interval; IQR, interquartile range; LS, least-squares; RT-qPCR, quantitative reverse transcription polymerase chain reaction; SC, subcutaneous; SD, standard deviation; SE, standard error.

Table S10. Number of Weeks of RT-qPCR Confirmed SARS-CoV-2 Infection (Regardless of Symptoms) by Baseline Serology Status

	Placebo	REGEN-COV 1200 mg SC
Seronegative		
n	104	100
Total, weeks	193	133
Total per 1000 participants, weeks	1855.8	1330.0
Reduction	-	28.3%
Per-participant, mean (SD), weeks	1.9 (1.3)	1.3 (1.1)
Seropositive		
n	38	46
Total, weeks	47	49
Total per 1000 participants, weeks	1236.8	1065.2
Reduction	-	13.9%
Per-participant, mean (SD), weeks	1.2 (1.3)	1.1 (1.0)
Seronegative, seropositive, and sero-undetermined		
n	156	155
Total, weeks	268	193
Total per 1000 participants, weeks	1717.9	1245.2
Reduction	-	27.5%
Per-participant, mean (SD), weeks	1.7 (1.3)	1.3 (1.1)

RT-qPCR, quantitative reverse transcription polymerase chain reaction; SC, subcutaneous; SD, standard deviation.

Table S11. Treatment-Emergent Adverse Events Occurring in $\geq 2\%$ of Participants

Preferred Term – no. of participants (%)	Placebo (N=156)	REGEN-COV 1200 mg SC (N=155)
Covid-19	49 (31.4)	34 (21.9)
Asymptomatic Covid-19*	12 (7.7)	7 (4.5)
Injection-site reaction	1 (0.6)	6 (3.9)

*Of these participants, 7 (4.4%) in the placebo group and 5 (3.2%) in the REGEN-COV group were confirmed to have a second positive infection with SARS-CoV-2 after their baseline infection was resolved (i.e., 2 negative RT-qPCR test results by central laboratory testing). The remaining 7 participants had a data entry error with the AE start time that resulted in the baseline infection reported as a TEAE; these participants did not have a TEAE of asymptomatic Covid-19.

AE, adverse event; RT-qPCR, quantitative reverse transcription polymerase chain reaction; SC, subcutaneous; TEAE, treatment-emergent adverse event.

Table S12. Serious Treatment-Emergent Adverse Events

System Organ Class Preferred Term – no. of participants (%)	Placebo (N=156)	REGEN-COV 1200 mg SC (N=155)
Participants with at least one serious TEAE	4 (2.6)	0
Infections and infestations	3 (1.9)	0
Covid-19	2 (1.3)	0
Covid-19 pneumonia	1 (0.6)	0
Gastrointestinal disorders	1 (0.6)	0
Pancreatitis acute	1 (0.6)	0

SC, subcutaneous; TEAE, treatment-emergent adverse event.

Table S13. Summary of PK Parameters for Casirivimab and Imdevimab After a Single 1200 mg Subcutaneous Dose of REGEN-COV in Part B Participants

PK Parameter ¹	REGN10933 (casirivimab)	REGN10987 (imdevimab)
C _{max} (mg/L)	47.5 (12.9) [4]	46.1 (13.8) [4]
t _{max} (day) ²	7.50 (4.00, 9.00) [4]	7.50 [4.00, 9.00] [4]
AUC ₀₋₂₈ (mg•day/L)	953 (213) [4]	840 (183) [4]
AUC _{inf} (mg•day/L) ³	2104 (515) [4]	1609 (419) [4]
C ₂₈ (mg/L) ^{3,4,5}	33.5 (12.3) [9]	26.9 (9.12) [9]
Half-life (day)	30.2 (5.31) [4]	26.5 (5.31) [4]

¹ Mean (SD) [N]; ² median (range) [N]; ³ value reported for subjects with %AUC_{inf} extrapolated <20%; ⁴ observed concentration 28 days after dosing, i.e., on day 29, as defined in the protocol; ⁵ value represents subjects in the sentinel and safety groups